| Literature DB >> 23056715 |
Hamid-Reza Kianifar1, Javad Akhondian, Mehri Najafi-Sani, Ramin Sadeghi.
Abstract
Practicing medicine according to the best evidence is gaining popularity in the medical societies. Although this concept, which is usually called Evidence Based Medicine (EBM) has been explained in many resources, it has not been addressed enough in pediatrics. In this review, we briefly explained Evidence Based Medicine approach and its applications in pediatrics in order to help the pediatricians to efficiently integrate EBM into their daily practice.Entities:
Keywords: Child; Critical appraisal; Evidence-based medicine; Pediatrics
Year: 2010 PMID: 23056715 PMCID: PMC3446038
Source DB: PubMed Journal: Iran J Pediatr ISSN: 2008-2142 Impact factor: 0.364
Steps of Evidence Based Medicine practice
|
|
|
|
|
|
|
|
PICO question of the patient
|
| A 2.5 year old boy with acute non-bloody diarrhea |
|
| Probiotic therapy with |
|
| Oral Re-hydration Therapy (ORT) |
|
| Decreased duration of diarrhea |
| Question | In a 2.5 year old boy with non-bloody diarrhea, how effective is probiotic therapy with |
Fig. 1The hierarchy of evidence according to Haynes RB. (Reproduced with permission from the publisher)[10]
Some free useful online resources for evidence based medicine
| Name of the site | Internet address | Type of resource |
|---|---|---|
|
|
| Synopsis |
|
|
| Summary |
|
|
| Search engine |
|
|
| Search engine |
|
|
| Summary |
|
| ||
|
|
| Summary |
|
| ||
|
|
| Synopsis |
|
|
| Summary |
|
|
| Summary |
|
|
| Search engine |
|
|
| Summary |
Oxford levels of evidence for therapeutic study designs#
| Level | Therapy/Prevention, Etiology/Harm |
|---|---|
|
| Systematic review (SR) (with homogeneity |
|
| Individual RCT (with narrow Confidence Interval) |
|
| All or none |
|
| SR (with homogeneity |
|
| Individual cohort study (including low quality RCT; e.g., <80% follow-up) |
|
| “Outcomes” Research; Ecological studies |
|
| SR (with homogeneity |
|
| Individual Case-Control Study |
|
| Case-series (and poor quality cohort and case-control studies |
|
| Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles” |
Reproduced with permission from Oxford levels of evidence for therapeutic study designs[19]
Homogeneity of a systematic review means that it is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies. Not all systematic reviews with statistically significant heterogeneity need be worrisome, and not all worrisome heterogeneity need be statistically significant. Studies displaying worrisome heterogeneity should be tagged with a “-” at the end of their designated level.
Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became available, but none now die on it.
Poor quality cohort study means one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a sufficiently long and complete follow-up of patients. By poor quality case-control study we mean one that failed to clearly define comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded), objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
Questions to be answered for assuring validity of the results of a RCT*
| Was the assignment of patients to treatments | |
| What is best? | Where do I find the information? |
|
| The |
| Were the groups | |
| What is best? | Where do I find the information? |
| If the randomisation process worked (that is, achieved comparable groups) the groups should be similar. The more similar the groups the better it is. | The |
| Aside from the allocated treatment, were groups treated equally? | |
| What is best? | Where do I find the information? |
| Apart from the intervention the patients in the different groups should be treated the same, eg additional treatments or tests. | Look in the |
| Were all patients who entered the trial accounted for? – and were they analyzed in the groups to which they were randomized? | |
| What is best? | Where do I find the information? |
| Losses to follow-up should be minimal – preferably less than 20%. However, if few patients have the outcome of interest, then even small losses to follow-up can bias the results. Patients should also be analyzed in the groups to which they were randomized – ‘ | The |
| Were measures | |
| What is best? | Where do I find the information? |
| It is ideal if the study is ‘double-blinded’ – that is, both patients and investigators are unaware of treatment allocation. If the outcome is | First, look in the |
Reproduced with permission from Critical appraisal for therapy articles [20]
Results of a putative study in a 2×2 format
| Number of events (cured) | Number of patients without event (not cured) | |
|---|---|---|